Not recruiting
Autoimmune haemolytic anaemia+1
Not recruitingStudy for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab
Registered drugNo placebo
Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab
Registered drugNo placebo
- Disease:Autoimmune haemolytic anaemiaNeoplasm malignant
- Substances:IbrutinibRuxolitinib+2
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Ibrutinib
